Role of Peroxisome Proliferator-Activated Receptor γ Ligands in the Vessel Wall
Die Rolle der Peroxisome proliferator-activated receptor γ-Liganden an der Gefäßwand
Alicja Jozkowicz
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna , the 2 Department of Clinical Biochemistry, Collegium Medicum, and the 3 Department of Cell Biochemistry, Institute of Molecular Biology, Jagiellonian University, Krakow, Poland, the 4 Division of Cardiology, Department of Internal Medicine, University of Innsbruck , and the 5 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorJ. Dulak
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna , the 2 Department of Clinical Biochemistry, Collegium Medicum, and the 3 Department of Cell Biochemistry, Institute of Molecular Biology, Jagiellonian University, Krakow, Poland, the 4 Division of Cardiology, Department of Internal Medicine, University of Innsbruck , and the 5 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorJ. Nanobashvili
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna , the 2 Department of Clinical Biochemistry, Collegium Medicum, and the 3 Department of Cell Biochemistry, Institute of Molecular Biology, Jagiellonian University, Krakow, Poland, the 4 Division of Cardiology, Department of Internal Medicine, University of Innsbruck , and the 5 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorM. Prager
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna , the 2 Department of Clinical Biochemistry, Collegium Medicum, and the 3 Department of Cell Biochemistry, Institute of Molecular Biology, Jagiellonian University, Krakow, Poland, the 4 Division of Cardiology, Department of Internal Medicine, University of Innsbruck , and the 5 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorI. Huk
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna , the 2 Department of Clinical Biochemistry, Collegium Medicum, and the 3 Department of Cell Biochemistry, Institute of Molecular Biology, Jagiellonian University, Krakow, Poland, the 4 Division of Cardiology, Department of Internal Medicine, University of Innsbruck , and the 5 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorAlicja Jozkowicz
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna , the 2 Department of Clinical Biochemistry, Collegium Medicum, and the 3 Department of Cell Biochemistry, Institute of Molecular Biology, Jagiellonian University, Krakow, Poland, the 4 Division of Cardiology, Department of Internal Medicine, University of Innsbruck , and the 5 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorJ. Dulak
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna , the 2 Department of Clinical Biochemistry, Collegium Medicum, and the 3 Department of Cell Biochemistry, Institute of Molecular Biology, Jagiellonian University, Krakow, Poland, the 4 Division of Cardiology, Department of Internal Medicine, University of Innsbruck , and the 5 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorJ. Nanobashvili
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna , the 2 Department of Clinical Biochemistry, Collegium Medicum, and the 3 Department of Cell Biochemistry, Institute of Molecular Biology, Jagiellonian University, Krakow, Poland, the 4 Division of Cardiology, Department of Internal Medicine, University of Innsbruck , and the 5 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorM. Prager
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna , the 2 Department of Clinical Biochemistry, Collegium Medicum, and the 3 Department of Cell Biochemistry, Institute of Molecular Biology, Jagiellonian University, Krakow, Poland, the 4 Division of Cardiology, Department of Internal Medicine, University of Innsbruck , and the 5 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorI. Huk
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna , the 2 Department of Clinical Biochemistry, Collegium Medicum, and the 3 Department of Cell Biochemistry, Institute of Molecular Biology, Jagiellonian University, Krakow, Poland, the 4 Division of Cardiology, Department of Internal Medicine, University of Innsbruck , and the 5 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorAbstract
enSummary: Background: Peroxisome proliferator-activated receptor-γ (PPARγ) is a ligand inducible transcription factor expressed mainly in adipose tissue and involved in regulation of lipid and glucose metabolism.Methods: Among the exogenous PPARγ ligands are thiazolidinediones (TZDs, insulin sensitizers), and nonsteroidal anti-inflammatory drugs (NSAID), whereas the endogenous inducers comprise prostaglandin D2 (PGD2) and prostaglandin J2 (PGJ2). Ligands of PPARγ are also involved in regulation of inflammation and angiogenesis.Results: Recently PPARγ has been detected in endothelium, vascular smooth muscle cells, and, to the highest extent, in macrophages/foam cells within atherosclerotic plaques.Conclusions: Here we summarize the possible roles played by PPARγ in the vessel wall.
Abstract
deZusammenfassung: Grundlagen: Peroxisome proliferator-activated receptor-γ (PPARγ) ist ein Liganden-induzierbarer Transkriptionsfaktor, der hauptsächlich im adipösen Gewebe exprimiert wird und in die Regulation der Lipid- und Glukosemetabolismen involviert ist.Methodik: Zu den exogenen PPARγ-Liganden gehören die Thiazolidindione (TZDs) und die nicht-steroidalen Antiphlogistika (NSAID). Prostaglandin D2 (PgD2) und Prostaglandin J2 (PgJ2) können PPARγ endogen induzieren. Die Liganden von PPARγ sind auch in der Regulation von Entzündung und Angiogenese involviert.Ergebnisse: Vor kurzem konnte PPARγ im Endothel, in den glatten Gefäßmuskulaturzellen und mit der höchsten Konzentration in Makrophagen/Schaumzellen in atherosklerotischen Plaques gemessen werden.Schlußfolgerungen: Wir fassen hier die möglichen Rollen, die PPARγ in der Gefäßwand spielt, zusammen.
References
- 1 Bendeck M, Zempo N, Clowes A, Galardy R, Reidy M: Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994; 75: 539 – 545.
- 2 Braun M, Schror K: Prostaglandin-D2 relaxes bovine coronary arteries by endothelium-dependent nitric oxide-mediated cGMP formation. Circ Res 1992; 71: 1305 – 1313.
- 3 Bui T, Straus DS: Effects of cyclopentenone prostaglandins and related compounds on insulin-like growth factor-I and Waf1 gene expression. Biochim Biophys Acta 1998; 1397: 31 – 42.
- 4 Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P and Evans RM: PPARγ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001; 7: 48 – 53.
- 5 Cominacini L, Garbin U, Fratta-Pasini A, Campagnola M, Davoli A, Foot E, Sighieri G, Sironi A, Lo Cascio V, Ferranini E: Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentrations in NIDDM patients. Diabetes 1998; 47: 130 – 133.
- 6 De Boer OJ, Van der Wal AC, Teeling P, Becker AE: Leukocyte requirement in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc Res 1999; 41: 443 – 449.
- 7 Duckers HJ, Boehm M, True AL, Yet SF, San H, Park JL, Webb RC, Lee ME, Nabel GJ, Nabel EG: Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med 2001; 7: 693 – 698.DOI: 10.1038/89068
- 8 Dulak J, Jozkowicz A, Dichtl W, Alber H, Schwarzacher SP, Pachinger O, Weidinger F: Vascular endothelial growth factor synthesis in vascular smooth muscle cells is enhanced by 7-ketocholesterol and lysophosphatidylcholine independently on their effect on nitric oxide generation. Atherosclerosis, in press.
- 9 Eguchi Y, Eguchi N, Oda H, Seiki K, Kijima Y, Matsu-ura Y, Urade Y, Hayashi O: Expression of lipocalin-type prostaglandin D synthase (β-trace) in human heart and accumulation in the coronary circulation of angina patients. Proc Natl Acad Sci USA 1997; 94: 14689 – 14694.
- 10 Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J: Organization, promoter analysis and expression of human PPARγ gene. J Biol Chem 1997; 272: 18779 – 18789.
- 11 Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 1995; 92: 657 – 671.
- 12 Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27 – 31.
- 13 Galis Z, Muszynski M, Sukhova G, Simon-Morrisey E, Unemori E, Lark M, Amento E, Libby P: Cytokine stimulated human vascular smooth muscle cell synthesize a complement of enzymes required for extracellular matrix degradation. Circ Res 1994; 75: 181 – 189.
- 14 Galis Z, Sukhova G, Lark M, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493 – 2503.
- 15 Garcia JGN, Verin AD, Herenyiova M, English D: Adherent neutrophils activate endothelial myosin light chain kinase: role in transendothelial migration. J Appl Physiol 1998; 84: 1817 – 1821.
- 16 Ghosh S, May MJ, Kopp EB: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225 – 260.
- 17 Goetze S, Xi XP, Kawano H, Gotlibowski T, Fleck E, Hsueh WA, Law RE: PPARγ-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 1999; 33: 798 – 806.
- 18 Greene ME, Pitts J, McCarville MA, Wang XS, Newport JA, Edelstein C, Lee F, Ghosh S, Chu S: PPARγ: observations in the hematopoietic system. Prostaglandins Other Lipid Mediat 2000; 62: 45 – 73.
- 19 Iijima K, Yoshizumi M, Ako J, Eto M, Kim S, Hashimoto M, Sugimoto N, Liang YQ, Sudoh N, Toba K, Ouchi Y: Expression of peroxisome proliferator-activated receptor-γ (PPARγ) in rat aortic smooth muscle cells. Biochem Biophys Res Commun 1998; 247: 353 – 356.
- 20 Ikeda Y, Sugawara A, Taniyama Y, Uruno A, Igarashi K, Arima S, Ito S, Takeuchi K: Suppression of rat thromboxane synthase gene transcription factor by peroxisome proliferator-activated receptor γ in macrophages via an interaction with NRF2. J Biol Chem 2000; 275: 33142 – 33150.
- 21 Inoue M, Itoh H, Tanaka T, Chun TH, Doi K, Fukunaga Y, Sawada N, Yamshita J, Masatsugu K, Saito T, Sakaguchi S, Sone M, Yamahara KI, Yurugi T, Nakao K: Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-γ. Arterioscler Thromb Vasc Biol 2001; 21: 560 – 566.
- 22 Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokine. Nature 1998; 391: 82 – 86.
- 23 Jozkowicz A, Dulak J, Piatkowska E, Placha W, Dembinska-Kiec A: Ligands of peroxisome proliferator-activated receptor-γ increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages. Acta Bioch Pol 2000; 47: 1147 – 1157.
- 24 Jozkowicz A, Dulak J, Prager M, Nanobashvili J, Nigisch A, Winter B, Weigel G, Huk I: Prostaglandin-J2 induces synthesis of interleukin-8 by endothelial cells in a PPARγ-independent manner. Prostaglandind Other Lipid Mediat 2001; 66: 165 – 177.
- 25 Jozkowicz A, Huk I, Nigisch A, Weigel G, Weidinger F, Dulak J: Effect of prostaglandin-J2 on VEGF synthesis depends on the induction of heme oxygenase-1. Antioxidant Redox Signal, in press.
- 26 Kato K, Sato H, Endo Y, Yamada D, Midorikawa S, Sato W, Mizuno K, Fujita T, Tsukamoto K, Watanabe T: Thiazolidinediones down-regulate plasminogen activator inhibitor type-1 expression in human vascular endothelial function. Biochem Biophys Res Commun 1999; 10: 431 – 435.
- 27 Kihara S, Ouchi N, Funahashi T, Shinohara E, Tamura R, Yamashita S, Matsuzawa Y: Troglitazone enhances glucose and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells. Atherosclerosis 1998; 136: 163 – 168.
- 28 Klemke RL, Cai S, Gianni AL, Gallagher PJ, De Lanerrolle P, Cheresh DA: Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997; 137: 481 – 492.
- 29 Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA: Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 2000; 101: 1311 – 1318.
- 30 Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98: 1897 – 1905.
- 31 Lee H, Schi W, Tontonoz P, Lee H, Shi W, Tontonoz P, Wang S, Subbanagounder G, Hedrick CC, Hama S, Borromeo C, Evans RM, Berliner JA, Nagy L: Role for peroxisome proliferator-activated receptor α in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and IL-8 by endothelial cells. Circ Res 2000; 87: 516 – 521.
- 32 Lehmann JM, Moore LB, Smith-Olivier TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-γ (PPARγ). J Biol Chem 1995; 270: 12953 – 12956.
- 33 Maines MD: The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997; 37: 517 – 554.
- 34 Mangelsdorf DJ, Evans RM: The RXR heterodimers and orphan receptors. Cell 1995; 83: 841 – 850.
- 35
Marx N,
Boucier T,
Sukhova GK,
Libby P,
Plutzky J: PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease.
Arterioscler Thromb Vasc Biol
1999; 19: 543 – 551.
10.1161/01.ATV.19.3.546 Google Scholar
- 36 Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J: Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097 – 1103.
- 37 Marx N, Sukhova GK, Collins T, Libby P, Plutzky J: PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999; 99: 3125 – 3131.
- 38 Marx N, Sukhova G, Murphy C, Libby P, Plutzky J: Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153: 17 – 23.
- 39 Michalik L, Wahli W: Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Curr Opin Biotech 1999; 10: 564 – 570.
- 40 Miwa Y, Sasaguri T, Inoue H, Taba Y, Ishida A, Abumiya T: 15-deoxy-Δ12,14-prostaglandin J2 induces G1 arrest and differentiation marker expression in vascular smooth muscle cells. Mol Pharmacol 2000; 58: 837 – 844.
- 41 Morikang E, Benson SC, Kurtz TW, Peshadsingh HA: Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am J Hypertens 1997; 10: 440 – 446.
- 42 Morita T, Kourembanas S: Endothelial vasoconstriction and growth factors is regulated by smooth muscle cell-derived carbon monoxide. J Clin Invest 1995; 96: 2676 – 2682.
- 43 Muise-Helmerics RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N: Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 1998; 273: 29864 – 29872.
- 44 Murao K, Imachi H, Momoi A, Sayo Y, Hosokawa H, Sato M, Ishida T, Takahara J: Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett 1999; 454: 27 – 30.
- 45 Murata T, He S, Hangai M, Ishibashi T, Xi XP, Kim S, Hsueh WA, Ryan SJ, Law RE, Hinton DR: Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 2000; 41: 2309 – 2317.
- 46 Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM: Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 1998; 93: 229 – 240.
- 47 Odani N, Negishi M, Takanashi S, Kitano Y, Kozutsumi Y, Ichikawa A: Regulation of BiP gene expression by cyclopentanone prostaglandins through unfolded protein response element. J Biol Chem 1996; 271: 16609 – 16613.
- 48 Osende JI, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, Zaman A, Rodriquez OJ, Lev EI, Rauch U, Helft G, Fallon JT, Crandall JP: Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol 2001; 38: 1307 – 1312.
- 49 Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis RJ, Flavell RA, Choi AM: Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nature Med 2000; 6: 422 – 428.
- 50 Palakhurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA: Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res 2001; 13: 6218.
- 51 Pasceri V, Wu HD, Willerson JT, Yeh ETH: Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 2000; 101: 235 – 238.
- 52 Patel SS, Thiagarajan R, Willerson JT, Yeh ETH: Inhibition of α4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in apoE-deficient mice. Circulation 1998; 97: 75 – 81.
- 53 Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witzum JL, Auwerx J, Palinski W, Glass CK: Expression of the peroxisome proliferator-activated receptor-γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density protein. Proc Natl Acad Sci USA 1998; 95: 7614 – 7619.
- 54 Ricote M, Li AC, Willson TW, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79 – 82.
- 55 Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santaro MG: Anti-inflammatory cyclopentanone prostaglandins are direct inhibitors of IkB kinase. Nature 2000; 403: 103 – 108.
- 56 Schall TJ, Bacon KB: Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 1994; 6: 865 – 873.
- 57 Schoonjans K, Steals B, Auwerx J: The peroxisome proliferator activated receptor (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochem Biophys Acta 1996; 1302: 93 – 109.
- 58 Schwartz S, Raskin P, Fonseca V, Graveline J: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 1998; 338: 861 – 866.
- 59 Shinohara E, Kihara S, Ouchi N, Funahashi T, Nakamura T, Yamashita S, Kameda-Katemura K, Matsuzawa Y: Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats. Atherosclerosis 1998; 136: 275 – 279.DOI: 10.1016/s0021-9150(97)00220-7
- 60 Soares MP, Lin Y, Anrather J, Csizmadia E, Takigami K, Sato K, Grey ST, Colvin RB, Choi AM, Poss KD, Bach FH: Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nature Med 1998; 4: 1073 – 1077.
- 61 Sood V, Colleran K, Burge MR: Thiazolidinediones: a comparative review of approved uses. Diabetes Technol Ther 2000; 2: 429 – 440.
- 62 Spirydopoulos I, Brogi E, Kearney M, Sullivan AB, Cetrulo C, Isner JM, Losordo DW: Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals. J Mol Cell Cardiol 1998; 29: 1321 – 1330.DOI: 10.1006/jmcc.1996.0365
- 63 Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalagsy LL, Ghosh G, Glass CK: 15-deoxy-?12,14-prostaglandin J2 inhibits multiple steps in the NFκB signaling pathway. Proc Natl Acad Sci USA 2000; 97: 4844 – 4849.
- 64 Taba Y, Sasaguri T, Miyagi M, Abumiya T, Miwa Y, Ikeda T, Mitsumata M: Fluid shear stress induces lipocalin-type prostaglandin D2 synthase expression in vascular endothelial cells. Circ Res 2000; 86: 967 – 973.
- 65 Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM: PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93: 241 – 252.
- 66 Wakino S, Kintscher U, Kim U, Yin F, Hsueh WA, Law RE: Peroxisome proliferator-activated receptor γ ligands inhibit retinoblastoma phosphorylation and G1 to S transition in vascular smooth muscle cells. J Biol Chem 2000; 275: 22435 – 22441.
- 67 Walch L, Labat C, Gascard JP, De Montpreville V, Brink C, Norel X: Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br J Pharmacol 1999; 126: 859 – 866.
- 68 Xin X, Yang S, Kowalski J, Gerritsen ME: Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999; 274: 9116 – 9121.
- 69 Yamakawa K, Hosoi M, Koyama H, Tanaka S, Fukumoto S, Morii H, Nishizawa Y: Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 2000; 271: 571 – 574.
- 70 Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, Farrar WL: Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPARγ) agonists. PPARγ co-association with transcription factor NFAT. J Biol Chem 2000; 275: 4541 – 4544.
- 71 Yonemitsu Y, Kaneda Y, Morishita R, Kazunori N, Nakashima Y, Sueishi K: Characterization of in vivo gene transfer into the arterial wall mediated by the sendai virus (hemagglutinating virus of Japan) liposomes: an effective tool for the in vivo study of arterial diseases. Lab Invest 1996; 75: 313 – 323.
- 72 Yoshimoto T, Naruse M, Shizume H, Naruse K, Tanabe A, Tanaka M, Tago K, Irie K, Muraki T, Demura H, Zardi L: Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 1999; 145: 333 – 340.DOI: 10.1016/s0021-9150(99)00085-4
